HepaRegeniX has demonstrated proof-of-efficacy in acute liver disease in preclinical studies performed in collaboration with the University Hospital of Tübingen (Germany) and the Mayo Clinic (Rochester, MN, USA).
Join us on 24 June and on 1 July 2020 for our webinars, presenting the top licensable projects in the field of gene and cell therapy from Ascenion’s and Oxford University Innovation’s (OUI) portfolios.
Newly founded dentalXrai provides a unique, AI-based platform to improve and speed up the analysis of dental X-ray images. Ascenion, technology transfer partner of the Charité – Universitätsmedizin Berlin, holds equity in the start-up.
Diffratec, a spin-off from the Medical University of Innsbruck (MUI), commercializes breakthrough diffractive elements. These elements, in particular Moiré lenses, are extremely compact and tunable with high speed and precision.
Formula Pharmaceuticals, a partner of the Max Delbrück Center for Molecular Medicine (MDC) has merged with cell therapy specialist CoImmune, with CoImmune as the surviving company. The new entity will continue its strategic partnership with the MDC.
Cardior Pharmaceuticals GmbH has published results of preclinical in vivo studies in Nature Communications showing that its lead compound, CDR132L, can significantly improve the functioning of pathologically altered hearts.
How to increase the social benefit of European research funding? Members of the ASTP’s National Associations’ Advisory Committee (NAAC) recently met representatives of the European Commission (EC) in Brussels to discuss this question.